Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 17/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260779 | 0.91 | SMO (0.64) | SMOMEN1HPGDCYP2C19KMT2A | |
| SCHEMBL4257702 | 0.89 | SMO (0.60) | SMOMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL4255817 | 0.88 | SMO (1.00) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL4253028 | 0.80 | SMO (0.81) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL4254597 | 0.80 | SMO (0.85) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL6525339 | 0.80 | SMO (0.80) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL4254933 | 0.79 | SMO (0.79) | SMOMEN1CYP2C19KMT2AMAPT | |
| SCHEMBL4263804 | 0.79 | SMO (0.74) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL4260923 | 0.77 | SMO (0.71) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL4262096 | 0.73 | SMO (0.66) | SMOMEN1CYP2C19KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | claimed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | SMO 1063/4885MEN1 1387/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.